Obesity Pillars最新文献

{"title":"Corrigendum to “Obesity pillars roundtable: Body mass index and body composition in black and female individuals. Race-relevant or racist? Sex-relevant or sexist?” [Obesity Pillars 4C (2022) 100044]","authors":"Harold Edward Bays , Sylvia Gonsahn-Bollie , Courtney Younglove , Sean Wharton","doi":"10.1016/j.obpill.2024.100105","DOIUrl":"10.1016/j.obpill.2024.100105","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100105"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400007X/pdfft?md5=e2ec63f3922a3ed3a882c1af3a0d02b5&pid=1-s2.0-S266736812400007X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","authors":"Harold Edward Bays,&nbsp;Carol Kirkpatrick,&nbsp;Kevin C. Maki,&nbsp;Peter P. Toth,&nbsp;Ryan T. Morgan,&nbsp;Justin Tondt,&nbsp;Sandra Michelle Christensen,&nbsp;Dave Dixon,&nbsp;Terry A. Jacobson","doi":"10.1016/j.obpill.2024.100108","DOIUrl":"10.1016/j.obpill.2024.100108","url":null,"abstract":"<div><h3>Background</h3><p>This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and cardiovascular disease (CVD) risk.</p></div><div><h3>Methods</h3><p>This joint expert review is based upon scientific evidence, clinical perspectives of the authors, and peer review by the OMA and NLA leadership.</p></div><div><h3>Results</h3><p>Among individuals with obesity, adipose tissue may store over 50% of the total body free cholesterol. Triglycerides may represent up to 99% of lipid species in adipose tissue. The potential for adipose tissue expansion accounts for the greatest weight variance among most individuals, with percent body fat ranging from less than 5% to over 60%. While population studies suggest a modest increase in blood low-density lipoprotein cholesterol (LDL-C) levels with excess adiposity, the adiposopathic dyslipidemia pattern most often described with an increase in adiposity includes elevated triglycerides, reduced high density lipoprotein cholesterol (HDL-C), increased non-HDL-C, elevated apolipoprotein B, increased LDL particle concentration, and increased small, dense LDL particles.</p></div><div><h3>Conclusions</h3><p>Obesity increases CVD risk, at least partially due to promotion of an adiposopathic, atherogenic lipid profile. Obesity also worsens other cardiometabolic risk factors. Among patients with obesity, interventions that reduce body weight and improve CVD outcomes are generally associated with improved lipid levels. Given the modest improvement in blood LDL-C with weight reduction in patients with overweight or obesity, early interventions to treat both excess adiposity and elevated atherogenic cholesterol (LDL-C and/or non-HDL-C) levels represent priorities in reducing the risk of CVD.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400010X/pdfft?md5=30611622cac9e760720255876287e7b2&pid=1-s2.0-S266736812400010X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140282296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presentation of a weight bias internalization tool for use in pregnancy and a call for future research: A commentary","authors":"Taniya S. Nagpal ,&nbsp;Nicole Pearce ,&nbsp;Kristi B. Adamo","doi":"10.1016/j.obpill.2024.100107","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100107","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence has shown that weight stigma is a concern during pregnancy, with several studies documenting common sources including healthcare, the media and interpersonal networks. Experiencing weight stigma may lead to weight bias internalization (WBI), whereby individuals accept and self-direct negative weight-related stereotypes, and limited research has assessed this in the context of pregnancy. Pregnancy is unique in terms of weight changes as many individuals will experience gestational weight gain (GWG). Accordingly, a WBI tool that accounts for GWG may be a more population-specific resource to use.</p></div><div><h3>Methods</h3><p>This commentary presents a pregnancy-specific WBI tool that accounts for GWG. The validated Adult WBI scale was modified to include ‘pregnancy weight gain’. This commentary also presents a brief summary of research that has assessed WBI in pregnancy and recommendations for future work.</p></div><div><h3>Results</h3><p>Recommended future work includes validation of the pregnancy-specific WBI tool and prospective examinations of weight stigma and WBI in pregnancy and implications on maternal and newborn outcomes.</p></div><div><h3>Conclusion</h3><p>Ultimately this research may inform development of interventions and resources to mitigate weight stigma and WBI in pregnancy and overall may contribute to improving prenatal outcomes and experiences.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000093/pdfft?md5=9573824bef1ff7702c798c57ee74ea4b&pid=1-s2.0-S2667368124000093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-centric prevention of cancer","authors":"Diego Anazco ,&nbsp;Andres Acosta ,&nbsp;Elizabeth J. Cathcart-Rake ,&nbsp;Stacy D. D'Andre ,&nbsp;Maria D. Hurtado","doi":"10.1016/j.obpill.2024.100106","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100106","url":null,"abstract":"<div><h3>Background</h3><p>The link between excess adiposity and carcinogenesis has been well established for multiple malignancies, and cancer is one of the main contributors to obesity-related mortality. The potential role of different weight-loss interventions on cancer risk modification has been assessed, however, its clinical implications remain to be determined. In this clinical review, we present the data assessing the effect of weight loss interventions on cancer risk.</p></div><div><h3>Methods</h3><p>In this clinical review, we conducted a comprehensive search of relevant literature using MEDLINE, Embase, Web of Science, and Google Scholar databases for relevant studies from inception to January 20, 2024. In this clinical review, we present systematic reviews and meta-analysis, randomized clinical trials, and prospective and retrospective observational studies that address the effect of different treatment modalities for obesity in cancer risk. In addition, we incorporate the opinions from experts in the field of obesity medicine and oncology regarding the potential of weight loss as a preventative intervention for cancer.</p></div><div><h3>Results</h3><p>Intentional weight loss achieved through different modalities has been associated with a reduced cancer incidence. To date, the effect of weight loss on the postmenopausal women population has been more widely studied, with multiple reports indicating a protective effect of weight loss on hormone-dependent malignancies. The effect of bariatric interventions as a protective intervention for cancer has been studied extensively, showing a significant reduction in cancer incidence and mortality, however, data for the effect of bariatric surgery on certain specific types of cancer is conflicting or limited.</p></div><div><h3>Conclusion</h3><p>Medical nutrition therapy, exercise, antiobesity medication, and bariatric interventions, might lead to a reduction in cancer risk through weight loss-dependent and independent factors. Further evidence is needed to better determine which population might benefit the most, and the amount of weight loss required to provide a clinically significant preventative effect.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000081/pdfft?md5=e755674535ec16622e68e439c1ba90c2&pid=1-s2.0-S2667368124000081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140063300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review","authors":"Dionysios V. Chartoumpekis ,&nbsp;Evagelia E. Habeos ,&nbsp;Aristea Psilopanagioti","doi":"10.1016/j.obpill.2024.100104","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100104","url":null,"abstract":"<div><h3>Background</h3><p>Hypothalamic obesity represents a clinical condition within the broader spectrum of obesity that frequently eludes detection and appropriate diagnosis. This subset of obesity is characterized by a dearth of established predictive markers and a paucity of standardized therapeutic protocols. The advent and rising prominence of glucagon-like peptide-1 (GLP-1) receptor agonists in the obesity treatment landscape present novel therapeutic avenues for hypothalamic obesity management. Nonetheless, critical inquiries persist concerning the efficacy of GLP-1 receptor (GLP-1R) agonists in this context, particularly regarding their central mechanisms of action and specific impact on hypothalamic obesity.</p></div><div><h3>Methods</h3><p>In this narrative review, we concentrate on analyzing research papers that delineate the detection and function of GLP-1 receptors across various hypothalamic and cerebral regions. Additionally, we examine clinical research papers and reports detailing the application of GLP-1 receptor agonists in treating hypothalamic obesity. Furthermore, we include a concise presentation of a clinical case from our unit for contextual understanding.</p></div><div><h3>Results</h3><p>Currently, the clinical evidence supporting the efficacy of GLP-1 receptor agonists in hypothalamic obesity, as well as the diverse characteristics of this obesity subtype, remains insufficient. Preliminary data suggest that GLP-1R agonists might offer an effective treatment option, albeit with variable outcomes, particularly in younger patient cohorts. From a mechanistic perspective, the presence of GLP-1 receptors in various hypothalamic and broader brain regions potentially underpins the efficacy of GLP-1R agonists, even in instances of hypothalamic damage. Nevertheless, additional research is imperative to establish the functional relevance of these receptors in said brain regions.</p></div><div><h3>Conclusion</h3><p>GLP-1R agonists represent a potential therapeutic option for patients with hypothalamic obesity. However, further clinical and basic/translational research is essential to validate the efficacy of these drugs across different presentations of hypothalamic obesity and to understand the functionality of GLP-1R in the diverse brain regions where they are expressed.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100104"},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000068/pdfft?md5=99a0c6546e411fd1fa3fe05da8516265&pid=1-s2.0-S2667368124000068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140024290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future of Obesity Medicine: Fearless 5-year Predictions for 2029 by Obesity Medicine Association Committee Chairs","authors":"Harold Bays","doi":"10.1016/j.obpill.2024.100102","DOIUrl":"10.1016/j.obpill.2024.100102","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100102"},"PeriodicalIF":0.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000044/pdfft?md5=0a08bdc874c99856dc09667843c5a3c2&pid=1-s2.0-S2667368124000044-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact Of body Mass Index on Cardiopulmonary Outcomes of COVID-19 Hospitalizations Complicated by Severe Sepsis","authors":"Sivaram Neppala ,&nbsp;Himaja Dutt Chigurupati ,&nbsp;Nikhilender Nag Mopuru ,&nbsp;Naga Ruthvika Alle ,&nbsp;Alpha James ,&nbsp;Ami Bhalodia ,&nbsp;Sajida Shaik ,&nbsp;Revanth Reddy Bandaru ,&nbsp;Athmananda Nanjundappa ,&nbsp;Praveena Sunkara ,&nbsp;Jyotsna Gummadi ,&nbsp;Rupak Desai","doi":"10.1016/j.obpill.2024.100101","DOIUrl":"10.1016/j.obpill.2024.100101","url":null,"abstract":"<div><h3>Background</h3><p>Body Mass Index (BMI) has a significant impact on Coronavirus disease (COVID-19) patient outcomes; however, major adverse cardiac and cerebrovascular outcomes in patients with severe sepsis have been poorly understood. Our study aims to explore and provide insight into its association.</p></div><div><h3>Methods</h3><p>This is an observational study looking at the impact of BMI on COVID-19-severe sepsis hospitalizations. The primary outcomes are adjusted odds of all-cause in-hospital mortality, respiratory failure, and major adverse cardiac and cerebrovascular events (MACCE), which include acute myocardial infarction, cardiac arrest, and acute ischemic stroke. The secondary outcome was healthcare resource utilization. Coexisting comorbidities and patient features were adjusted with multivariable regression analyses.</p></div><div><h3>Results</h3><p>Of 51,740 patients with severe COVID-19-sepsis admissions, 11.4% were overweight, 24.8% had Class I obesity (BMI 30–34.9), 19.8% had Class II obesity (BMI 35–39.9), and 43.9% had the categorization of Class III obesity (BMI &gt;40) cohorts with age&gt;18 years. The odds of MACCE in patients with class II obesity and class III obesity (OR 1.09 and 1.54; 95CI 0.93–1.29 and 1.33–1.79) were significantly higher than in overweight (p &lt; 0.001). Class I, Class II, and Class III patients with obesity revealed lower odds of respiratory failure compared to overweight (OR 0.89, 0.82, and 0.82; 95CI 0.75–1.05, 0.69–0.97, and 0.70–0.97), but failed to achieve statistical significance (p = 0.079). On multivariable regression analysis, all-cause in-hospital mortality revealed significantly higher odds in patients with Class III obesity, Class II, and Class I (OR 1.56, 1.17, and 1.06; 95CI 1.34–1.81, 0.99–1.38, and 0.91–1.24) vs. overweight patients (p &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>Patients with Class II and Class III obesity had significantly higher odds of MACCE and in-hospital mortality in COVID-19-severe sepsis admissions.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100101"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000032/pdfft?md5=eb4ad92f198389c7f9c1186adcb2e3e4&pid=1-s2.0-S2667368124000032-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139873065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact Of body Mass Index on Cardiopulmonary Outcomes of COVID-19 Hospitalizations Complicated by Severe Sepsis","authors":"Sivaram Neppala, H. Chigurupati, Nikhilender Nag Mopuru, Naga Ruthvika Alle, Alpha James, Ami Bhalodia, Sajida Shaik, Revanth Reddy Bandaru, Athmananda Nanjundappa, P. Sunkara, Jyotsna Gummadi, Rupak Desai","doi":"10.1016/j.obpill.2024.100101","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100101","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"174 S400","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139812778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient perceptions of three-dimensional (3D) surface imaging technology and traditional methods used to assess anthropometry","authors":"Lucie Nield ,&nbsp;Michael Thelwell ,&nbsp;Audrey Chan ,&nbsp;Simon Choppin ,&nbsp;Steven Marshall","doi":"10.1016/j.obpill.2024.100100","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100100","url":null,"abstract":"<div><h3>Background</h3><p>Obesity and overweight are commonplace, yet attrition rates in weight management clinics are high. Traditional methods of body measurement may be a deterrent due to invasive and time-consuming measurements and negative experiences of how data are presented back to individuals. Emerging new technologies, such as three-dimensional (3D) surface imaging technology, might provide a suitable alternative. This study aimed to understand acceptability of traditional and 3D surface imaging-based body measures, and whether perceptions differ between population groups.</p></div><div><h3>Methods</h3><p>This study used a questionnaire to explore body image, body measurement and shape, followed by a qualitative semi-structured interview and first-hand experience of traditional and 3D surface imaging-based body measures.</p></div><div><h3>Results</h3><p>49 participants responded to the questionnaire and 26 participants attended for the body measurements and interview over a 2-month period. There were 3 main themes from the qualitative data 1) Use of technology, 2) Participant experience, expectations and perceptions and 3) Perceived benefits and uses.</p></div><div><h3>Conclusion</h3><p>From this study, 3D-surface imaging appeared to be acceptable to patients as a method for anthropometric measurements, which may reduce anxiety and improve attrition rates in some populations. Further work is required to understand the scalability, and the role and implications of these technologies in weight management practice. (University Research Ethics Committee reference number ER41719941).</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100100"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000020/pdfft?md5=9dab2a1581b7d3d2e928b4fa76354a34&pid=1-s2.0-S2667368124000020-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of phentermine / topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: A randomized, multicenter, double-blind study","authors":"Harold E. Bays ,&nbsp;Daniel S. Hsia ,&nbsp;Lan T. Nguyen ,&nbsp;Craig A. Peterson ,&nbsp;Santosh T. Varghese","doi":"10.1016/j.obpill.2024.100099","DOIUrl":"10.1016/j.obpill.2024.100099","url":null,"abstract":"<div><h3>Background</h3><p>A fixed-dose combination of phentermine and extended-release topiramate (PHEN/TPM - approved for weight management) has demonstrated in-clinic reduction of blood pressure (BP). Ambulatory BP monitoring (ABPM) may be a better predictor of cardiovascular disease risk than in-clinic BP.</p></div><div><h3>Methods</h3><p>This randomized, multicenter, double-blind study enrolled 565 adults with overweight/obesity. Inclusion criteria included participants willing to wear ABPM device for 24 h. Exclusion criteria included screening blood pressure &gt;140/90 mmHg and antihypertensive medications not stable for 3 months prior to randomization. Participants received placebo (n = 184), phentermine 30 mg; (n = 191), or PHEN 15 mg/TPM 92 mg; (n = 190). 24-hour ABPM was performed at baseline and at week 8. The primary endpoint was mean 24-h systolic BP (SBP) as measured by ABPM, in the per protocol population.</p></div><div><h3>Results</h3><p>Participants were mostly female (73.5 ​%) and White (81.6 ​%), with a mean age of 53.4 years; 32.4 ​% had no hypertension diagnosis or treatment, 62.5 ​% had hypertension using 0 to 2 antihypertensive medications, and 5.1 ​% had hypertension using ≥ 3 antihypertensive medications. Baseline mean SBP/diastolic BP (DBP) was 123.9/77.6 ​mmHg. At week 8, mean SBP change was −0.1 ​mmHg (placebo), +1.4 ​mmHg (phentermine 30 ​mg), and −3.3 ​mmHg (PHEN/TPM). Between-group difference for PHEN/TPM versus placebo was −3.2 ​mmHg (95 ​% CI: -5.48, -0.93 ​mmHg; p ​= ​0.0059). The between-group difference for PHEN/TPM versus phentermine 30 ​mg was −4.7 ​mmHg (95 ​% CI: −6.96, −2.45 ​mmHg; p ​&lt; ​0.0001). Common (&gt;2 ​% in any treatment group) adverse events (i.e., dry mouth, constipation, nausea, dizziness, paresthesia, dysgeusia, headache, COVID-19, urinary tract infection, insomnia, and anxiety) were mostly mild or moderate.</p></div><div><h3>Conclusions</h3><p>In this randomized, multicenter, double-blind ABPM study, PHEN/ TPM reduced SBP compared to either placebo or phentermine 30 mg (Funding: Vivus LLC; ClinicalTrials.gov: <span>NCT05215418</span><svg><path></path></svg>).</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100099"},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000019/pdfft?md5=af3a54e4dff0c78a5b9dd3deedb8b337&pid=1-s2.0-S2667368124000019-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139455543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}